PD-1 inhibitors, such as nivolumab, can activate T cells to kill tumor cells by blocking the binding of the PD-1 receptor and programmed death ligand 1 and ligand 2 (PD-L1 and PD-L2) [3]. The gene discussed is CD274; the disease is neoplasm.